Medical Advocates
HIV Protease Inhibitors
  General Data Specific PIs
New and Noteworthy
 General Reports
 Pharmacokinetics
Viral Dynamics
Drug/Drug Interactions
 Resistance/Cross Resistance
Adverse Events
 Adherence
 Treatment Strategies
 Diagnostics/Monitoring
 Pregnancy/Neonatal
Pediatric Data
Non-HIV Indications 		Amprenavir
Atazanavir
Darunavir
Fosamprenavir
Indinavir
Lopinavir/Ritonavir
Nelfinavir
Ritonavir
Saquinavir
Tipranavir

 
Drugs Main Page HIV Main Page Main New/Newsworthy Home    

Last Update:  December 31, 2011
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
 
December  2011
 
General/Miscellaneous Reports
 
     Journal Papers, Abstracts, and Commentaries
 
 
Complex Drug Interactions of the HIV Protease Inhibitors 3: Effect of Simultaneous or Staggered
Dosing of Digoxin and Ritonavir, Nelfinavir, Rifampin or Bupropion.
Kirby BJ, Collier AC, Kharasch ED,  et al
 Drug Metab Dispos. 2011 Dec 21.
Abstract

Influence of drug transport proteins on the pharmacokinetics and drug interactions of
HIV protease inhibitors.
Griffin L, Annaert P, Brouwer KL.
J Pharm Sci. 2011 Jun 22. .
 Abstract

HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.
Alfonso Y, Monzote L.
Open Med Chem J. 2011;5:40-50
Abstract

Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor
regimen.
Lillemark MR, Gerstoft J, Obel N, et al
J Med Virol. 2011 Mar;83(3):377-383
Abstract

Comparative Molecular Field Analysis of a Series of Inhibitors of HIV-1 Protease.
Ferreira LG, Leitão A, Montanari CA, Andricopulo AD.
Med Chem. 2011 Jan 11.
 Abstract

HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
Berginc K, Trdan T, Trontelj J, Kristl A.
 Biopharm Drug Dispos. 2010 Oct 26.
 Abstract

Boosted Protease Inhibitor Monotherapy. What Have We Learnt after Seven Years
of Research?
Pulido F, Matarranz M, Rodríguez-Rivera V,  et al
AIDS Rev. 2010 Jul-Sep;12(3):127-134
 Abstract

Human immunodeficiency virus protease inhibitors reduce the growth of human
tumors via a proteasome-independent block of angiogenesis and matrix
metalloproteinases.
 Toschi E, Sgadari C, Malavasi L, et al
Int J Cancer. 2010 Jul 8
 Abstract

Gag Mutations Can Impact Virological Response to Dual Boosted
Protease Inhibitor Combinations in Antiretroviral Naive HIV Infected
Patients (2 IP - ANRS 127 trial).|
Larrouy L, Chazallon C, Landman R, et al
Antimicrob Agents Chemother. 2010 May 3
 Abstract

Protease inhibitor-based antiretroviral therapy in treatment-naive
HIV-1-infected patients: the evidence behind the options.
Naggie S, Hicks C.
J Antimicrob Chemother. 2010 Apr 23.
 Abstract

HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36
and CPT-I fatty acid transporters.
Richmond SR, Carper MJ, Lei X, et al 
Biochim Biophys Acta. 2010 Jan 28.
 Abstract

HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired
lipodystrophy in patients on highly active antiretroviral therapy?|
Goulbourne CN, Vaux DJ. 
J Biochem Soc Trans. 2010 Feb;38(Pt 1):292-6.
 Abstract

HIV-1 protease inhibitors. A review for clinicians.
Deeks SG, Smith M, Holodniy M, Kahn JO.
JAMA. 1997 Jan 8;277(2):145-53.
 Abstract

HIV Protease Inhibitors Induce ER Stress and Disrupt Barrier Integrity in Intestinal
Epithelial Cells.
Wu X, Sun L, Zha W, Studer E, et al
Gastroenterology. 2009 Sep 1.
Abstract

HIV protease inhibitors: recent clinical trials and recommendations on use.
Fernández-Montero JV, Barreiro P, Soriano V.
Expert Opin Pharmacother. 2009 Jul;10(10):1615-29.
 Abstract

Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
Struble KA, Chan-Tack KM, Soon GG.
 Curr Opin HIV AIDS. 2008 Nov;3(6):676-80.
 Abstract

Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in Subjects Receiving HAART
During Acute or Early HIV Infection.
Ernstrom KB, Little SJ, Routy JP, et al
 J Acquir Immune Defic Syndr. 2009 Feb 3.
 Abstract

Protease inhibitor therapy in resource-limited settings.
Elliott JH, Pujari S.
 Curr Opin HIV AIDS. 2008 Nov;3(6):612-619
 Abstract
 

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF, van Agtmael MA, Nijhuis M, et al
 AIDS. 2008 Dec 24.
Abstract
 
Boosted Protease Inhibitor-Based or Nonnucleoside Reverse Transcriptase-Based HAART:
Is There a Best Choice for Antiretroviral-Naive HIV-1 Infected Patients?
 Cuzin L, Allavena C, Morlat P, Dellamonica P.
 AIDS Rev. 2008 Oct-Dec;10(4):205-11.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Nucleoside-Free Boosted Double PI Regimen: Significant CD4(+) T-Cell Recovery in Patients
with Poor Immunologic Response Despite Virologic Suppression.
Lehmann C, Jung N, Hofmann A, et al
Curr HIV Res. 2008 Nov;6(6):555-9
 Abstract
 
Perceived stress and norepinephrine predict the effectiveness of response to protease inhibitors in HIV.
Ironson G, Balbin E, Stieren E, et al
Int J Behav Med. 2008;15(3):221-6.
 Abstract
 
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M, O'Brien D, 
AIDS. 2008 Jul 11;22(11):1305-12.
Abstract
 
Design of HIV Protease Inhibitors Targeting Protein Backbone: An Effective Strategy for
Combating Drug Resistance.
Ghosh AK, Chapsal BD, Weber IT, Mitsuya H.
Acc Chem Res. 2007 Aug 28;
Abstract
 
Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems.
Garrett NJ, Matin N, Edwards SG, Miller RF.
AIDS. 2007 Aug 20;21(13):1821-3
 Abstract
 
HIV Protease Inhibitors Enhance the Efficacy of Irradiation.
Cuneo KC, Tu T, Geng L, et al 
Cancer Res. 2007 May 15;67(10):4886-93.
 Abstract
 
HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis
nduced by combined treatment TNF-alpha+TSA.
Vandergeeten C, Quivy V, Moutschen M, et al 
Biochem Pharmacol. 2007 Feb 24;
 Abstract
 
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a
boosted protease inhibitor.
Grant P, Taylor J, Cain P, Short W, et al
Clin Infect Dis. 2009 Mar 1;48(5):680-2.
 Abstract
 
Flying in the Face of Resistance: Antiviral-independent Benefit of HIV Protease Inhibitors
on T-cell Survival.
Vlahakis SR, Bren GD, Algeciras-Schimnich A, et al 
Clin Pharmacol Ther. 2007 Mar 14;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among
HIV-infected adults in routine clinical practice.
Molto J, Blanco A, Miranda C, Miranda J, et al
Br J Clin Pharmacol. 2007 Jan 12;
 Abstract
 
Acid suppressive therapy and the effects on protease inhibitors.
Fulco PP, Vora UB, Bearman GM. 
Ann Pharmacother. 2006 Nov;40(11):1974-83.
 Abstract
 
Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside
reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
 Chou R, Fu R, Huffman LH, Korthuis PT.
Lancet. 2006 Oct 28;368(9546):1503-15.
 Abstract
 
Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing
antiretroviral therapy.
Rodes B, Sheldon J, Toro C,  et al
J Antimicrob Chemother. 2006 Feb
Abstract
 
Postprandial response to a physiologic caloric load in HIV-positive patients receiving
protease inhibitor-based or nonnucleoside reverse transcriptase inhibitor-based antiretroviral
therapy.
Thomas-Geevarghese A, Raghavan S, Minolfo R, et al   
Am J Clin Nutr. 2005 Jul;82(1):146-54.
 Abstract
 
Prescribing of Contraindicated Protease Inhibitor and Statin Combinations Among
HIV-Infected Persons.
Hulgan T, Sterling TR, Daugherty J, et al 
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):277-282.
Abstract
 
FULL-TEXT PDF ARTICLE
 The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART)
on health-related quality of life.
 Eriksson LE, Bratt GA, Sandstrom E, Nordstrom G.
 Health Qual Life Outcomes. 2005 May 4;3(1):32
 Paper
 
The impact of HIV-protease inhibitors on opportunistic parasites.
Pozio E, Morales MA. et al    
Trends Parasitol. 2005 Feb;21(2):58-63.
 Abstract

Tolerability and Safety of HIV Protease Inhibitors in Adults.
Sax PE, Kumar P.  
J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-1124
 Abstract
 
Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors.
Bermejo M, Sanchez-Palomino S, Usan L, Alcami J. 
J Med Virol. 2004 Aug;73(4):502-7.
Abstract
 
Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
Bucher HC, Young J, Battegay M.  
J Antimicrob Chemother. 2004 Jul 21
 Abstract
 
Transport of HIV Protease Inhibitors Through the Blood-Brain Barrier and Interactions With
the Efflux Proteins, P-Glycoprotein and Multidrug Resistance Proteins.
Gimenez F, Fernandez C, Mabondzo A.
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):649-658
 Abstract
 
Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview.
Losina E, Islam R, Pollock AC, et al  
 Clin Infect Dis. 2004 Jun 1;38(11):1613-22.
 Abstract
 
Attitudes toward HIV protease inhibitors and medication adherence in an inner city
HIV population.
Demmer C.
AIDS Patient Care STDS. 2003 Nov;17(11):575-80.
 Abstract
 
FULL-TEXT PDF PUBLICATION
The HIV Protease Inhibitors
 The Drug Advisor Volume 2. No 8 August 2003
 Paper

Simplification of antiretroviral treatment--how to sustain success, reduce toxicity
and ensure adherence avoiding PI use.
 Barreiro P, Garcia-Benayas T, Soriano V, Gallant
J. AIDS Rev 2002 Oct-Dec;4(4):233-41
 Abstract

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance.
 Hugen PW, Burger DM, Aarnoutse RE,et al|
 Ther Drug Monit 2002 Oct;24(5):579-87
 Abstract

Factors associated with mortality in human immunodeficiency virus type  1-infected
adults initiating protease inhibitor-containing therapy: role of education level and of
early transaminase level elevation (APROCO-ANRS EP11 study).
 The Antiproteases Cohorte Agence Nationale de Recherches sur
le SIDA EP 11 study.Lewden C, Raffi F, Cuzin L, et al
 J Infect Dis 2002 Sep 1;186(5):710-4
 Abstract
 
HIV-1 Protease Inhibitors- A Review for Clinicians.
Deeks, SG, Smith M, Holodniy M et al.
JAMA 1997; 277(2): 145-53.
Abstract
 

 
     Conference Reports, Abstracts, and Posters
 
 
POSTER
 The impact of NNRTIs compared to PIs on the development of cancer:
is there a difference?
N. Crum-Cianflone, K. Huppler Hullsiek, A. Ganesan, et al 
(5th IAS Conference)
PDF Poster     Abstract

Tolerability of boosted protease inhibitor therapy in clinical practice
 DV Condoluci, M Andrews, PD Slowinski, et al
(8th Int Congress on Drug Therapy in HIV Infection)
 Abstract

Lipid profile using of the new protease inhibitors in antiretroviral treated HIV-infected patients
 E Negredo, P Echeverria, J Puig,  et al
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
A randomized, prospective comparison of three hypoglycemic agents in HIV-infected patients
receiving protease inhibitors, who developed insulin resistance and glucose intolerance
 L Calza
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
Comparison of single and boosted-protease-inhibitor (PI) versus non-nucleoside reverse
transcriptase inhibitor (NNRTI) containing regimens in previously antiretroviral naive patients
 A Mocroft, O Kirk, A Horban
 (8th Int Congress on Drug Therapy in HIV Infection)
 Abstract
 
HIV Protease Inhibitor Blocks gp120-induced CD4 T-cell Death by Preventing Mitochondrial
Destabilization
S Vlahakis, G Bren, S Trushin, et al
(13 CROI)
 Abstract
 
Morbidity During the 5 Years Following Initiation of Protease Inhibitor Therapy in HIV-Infected
Patients
V. LE MOING,  G. CHÊNE , L. CUZIN ,  et al 
 (45 ICAAC)
 Abstract
 
CD14+/CD16+ Monocytes Are Enriched in Cerebrospinal Fluid of HIV-1-infected
Individuals on Protease Inhibitors
JK Neuenburg, N Lollo, R Price,  R Grant
(12 CROI)
Abstract
 
Pharmacokinetics Data
 

     Journal Papers, Abstracts, and Commentaries

 
HIV Protease Inhibitors Activate the Unfolded Protein Response and Disrupt Lipid Metabolism in
Primary Hepatocytes.
Zhou H, Gurley EC, Jarujaron S ,et al
Am J Physiol Gastrointest Liver Physiol. 2006 Jul 20;
 Abstract
 
The management of HIV-1 protease inhibitor pharmacokinetic interactions.
Winston A, Boffito M.
J Antimicrob Chemother. 2005 Jun 7;
 Abstract
 
The pharmacokinetics of HIV protease inhibitor combinations.
Boffito M, Maitland D, Samarasinghe Y, Pozniak A. 
Curr Opin Infect Dis. 2005 Feb;18(1):1-7.
 Abstract

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome:
A potential mechanism for protease inhibitor-induced hyperlipidemia.
 Liang JS, Distler O, Cooper DA, et al.
Nat Med 2001 Dec;7(12):1327-31
 Abstract

  

     Conference Reports, Abstracts, and Posters

 
Human immunodeficiency virus protease inhibitors accumulate into cultured human
adipocytes and alter expression of adipocytokines
 CV Vernochet, S Azoulay, D Duval, et al
 (15IAC)
 Abstract
Drug/Drug Interactions Data
 
     Journal Papers, Abstracts, and Commentaries
 
 
Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with
Nonnucleoside Reverse Transcriptase Inhibitor-, Protease Inhibitor-, and Raltegravir-Based
Antiretroviral Regimens (March).
Patel N, Abdelsayed S, Veve M, Miller CD.
 Ann Pharmacother. 2011 Mar 8.
 Abstract  

A WEEK-IN REVIEW FEATURED REPORT
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a
ritonavir-boosted protease inhibitor or raltegravir.
Bickel M, Anadol E, Vogel M, et al 
J Antimicrob Chemother. 2010 Mar
Abstract  

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
Annaert P, Ye ZW, Stieger B, Augustijns P.
Xenobiotica. 2010 Jan 27.
Abstract  

Pharmacokinetics and Pharmacodynamics of Sildenafil in a Patient Treated With Human
Immunodeficiency Virus Protease Inhibitors.
Aschmann YZ, Kummer O, Linka A, et al 
Ther Drug Monit. 2008 Feb;30(1):130-134.
 Abstract  
 
Drug Interactions between HIV Protease Inhibitors and Acid-Reducing Agents.
Falcon RW, Kakuda TN.
Clin Pharmacokinet. 2008;47(2):75-89.
 Abstract  
 
Quantitative Assessment of HIV-1 Protease Inhibitor Interactions with Drug Efflux Transporters
in the Blood-Brain Barrier.
Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 
Pharm Res. 2005 Aug;22(8):1259-68
 Abstract  

Drug interactions between HIV protease inhibitors based on physiologically-based
pharmacokinetic model.
 Shibata N, Gao W, Okamoto H, et al.
J Pharm Sci 2002 Mar;91(3):680-9
Abstract  

 
Viral Dynamics
 
     Journal Papers, Abstracts, and Commentaries
 
  Review: Immunologic Response to Protease Inhibitor-Based Highly Active Antiretroviral
Therapy: A Review.
 Wainberg MA, Clotet B.
AIDS Patient Care STDS. 2007 Sep;21(9):609-620.
 Abstract
 
  Virological and immunological outcomes at 3 years after starting antiretroviral therapy with
regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or
both in NITIO: open-label randomised trial.INITIO Trial
International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, et al 
Lancet. 2006 Jul 22;368(9532):287-98
 Abstract
 
  Mechanisms of early virologic failure in antiretroviral-naive patients starting protease
inhibitor-containing regimens: the APROVIR Study
 Masquelier B, Peytavin G, Leport C, et al
 J Infect Dis 2002 Nov 15;186(10):1503-7
 Abstract
 
  Predictors of virological rebound in HIV-1-infected patients initiating a protease
inhibitor-containing regimen.
Le Moing V, Chene G, Carrieri MP , et al.
AIDS 2002 Jan 4;16(1):21-29 
Abstract
   
  Impact of discontinuation of initial protease inhibitor therapy on further virological
response in a cohort of human immunodeficiency virus-infected patients.
 Le Moing V, Chene G, Leport C, et al.
Clin Infect Dis 2002 Jan 15;34(2):239-47
 Abstract 

     Conference Reports, Abstracts, and Posters

 
POSTER
 The effect of antiretroviral protease inhibitors on P-gp expression in CD4 and CD8
subpopulations of lymphocytes.
Ford J, Chandler B, Khoo SH, Back DJ , et al.
(4th Pharmacology Workshop)
 PDF Poster
 
MDR1 Genotype May Influence CD4+ T-cell P-glycoprotein Activity in HIV-1-infected
Persons Receiving Protease Inhibitors
 T Hulgan, J Donahue, R Kim,et al
 (11 CROI)
 Abstract
 
Distinct cross-resistance profiles of the new protease inhibitors (PI) Amprenavir,
Lopinavir, and Atazanavir in a panel of clinical samples
 B Schmid, T Schnell , G Moschik, et al
(1st European HIV Drug Resistance Workshop)
 Abstract
 
Protease inhibitors cross-resistance
F Maggiolo, A Callegaro, D Ripamonti, et al.
(1st European HIV Drug Resistance Workshop)
 Abstract
Adherence
 

     Journal Papers, Abstracts, and Commentaries

 
Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.
Blaschke TF.
 Curr Opin HIV AIDS. 2008 Nov;3(6):603-7
 Abstract

Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring
Mutations in NNRTI- or PI-Treated Patients.
 Maggiolo F, Airoldi M, Kleinloog HD, et al
 HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
Abstract
 
Regimen-dependent variations in adherence to therapy and virological suppression in
patients initiating protease inhibitor-based highly active antiretroviral therapy.
 Moore DM, Hogg RS, Yip B, et al
HIV Med. 2006 Jul;7(5):311-6.
 Abstract
 
The social realities of adherence to protease inhibitor regimens: substance use, health care
and psychological States.
 Halkitis PN, Kutnick AH, Slater S. et al
J Health Psychol. 2005 Jul;10(4):545-58.
Abstract  
 
Treatment Strategies
 

     Journal Papers, Abstracts, and Commentaries
 
Protease Inhibitors as Preferred Initial Regimen for Antiretroviral-Naive HIV Patients.
Tejerina F, López Bernaldo de Quirós JC.
AIDS Rev. 2011 Oct;13(4):227-33.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy:
A Meta-Analysis
Mathis S, Khanlari B, Pulido F,  et al
PLoS ONE 6(7): e22003
  Paper

FULL-TEXT ARTICLE
Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs.
Continuous Therapy for HIV-1 Infection
Firnhaber C, Azzoni L, Foulkes AS, et al  
PLoS One. 2011;6(6):e21450.
 Paper

A WEEK-IN-REVIEW FEATURED REPORT
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination
or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
 Bommenel T, Launay O, Meynard JL, et al
J Antimicrob Chemother. 2011 Jun 1
 Abstract

Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and
Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E
Collaboration Study Group.
Benard A, van Sighem A, Taieb A,  et al
Clin Infect Dis. 2011 May;52(10):1257-1266
Abstract

Protease inhibitor monotherapy.
Pérez-Valero I, Arribas JR.
Curr Opin Infect Dis. 2010 Dec 9.
 Abstract

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17
dose-ranging pharmacokinetic trials.
Hill A, van der Lugt J, Sawyer W, Boffito M.
AIDS. 2009 Oct 3.
 Abstract

Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?
Winston A, Khoo S.
 Curr Opin HIV AIDS. 2008 Nov;3(6):608-11.
 Abstract

Double-boosted protease inhibitor antiretroviral regimens: what role?
Ribera E, Curran A.
Drugs. 2008;68(16):2257-67.
Abstract
 
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.
AIDS. 2008 Jul 11;22(11):1305-12.
 Abstract
 
Ezetimibe Combined with Low-Dose Statin Effectively Lowers LDL in Protease Inhibitor
Treated Patients.
Berg-Wolf MV, Klibanov OM, Gaughan JP, Tedaldi EM.
AIDS Patient Care STDS. 2008 Ma
 Abstract
 
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
Youle M. 
J Antimicrob Chemother. 2007 Sep 25;
Abstract
 
Superior virological response to boosted protease inhibitor-based highly active antiretroviral
therapy in an observational treatment programme.
Wood E, Hogg R, Yip B, Moore D, et al
HIV Med. 2007 Mar;8(2):80-5.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Martinez E, Arnaiz JA, Podzamczer D, et al 
AIDS. 2007 Jan 30;21(3):367-369.
 Abstract
 
A comparison of three highly active antiretroviral treatment strategies consisting of
non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the
presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058
FIRST Study): a long-term randomised trial.
 MacArthur RD, Novak RM, Peng G, et al 
Lancet. 2006 Dec 16;368(9553):2107-9.
Abstract
 
Effects of discontinuing Stavudine or protease inhibitor therapy on human immunodeficiency
virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
 Tavassoli N, Bagheri H, Sommet A, et al
Pharmacotherapy. 2006 Feb;26(2):154-61
 Abstract
 
Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression
in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as
compared with standard triple therapy.
Portilla J, Boix V, Garcia-Henarejos JA, et al;
Int J STD AIDS. 2005 Dec;16(12):807-810.
Abstract
 
Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly
active antiretroviral therapy is resumed after treatment interruption.
Barreiro P, de Mendoza C, Gonzalez-Lahoz J, Soriano V.
Clin Infect Dis. 2005 Sep 15;41(6):897-900.
 Abstract
 
FULL-TEXT ARTICLE
 Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or
non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of
controlled trials.
Yazdanpanah Y, Sissoko D, Egger M, et al
BMJ  2004;328:249 
 Paper
 
Meta-analysis of randomized controlled trials of simplified versus continued protease
inhibitor-based antiretroviral therapy in HIV-1-infected patients.
Bucher HC, Kofler A, Nuesch R,et al
AIDS. 2003 Nov 21;17(17):2451-9.
 Abstract
 
Increased use of lipid-lowering therapy in patients receiving human immunodeficiency  
virus protease inhibitors.
Stein JH, Wu Y, Kawabata H, Iloeje UH.
Am J Cardiol. 2003 Aug 1;92(3):270-4.
Abstract

Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of
protease inhibitors.
 Washington CB, Flexner C, Sheiner  LB, et al.
Clin Pharmacol Ther 2003 May;73(5):406-16
 Abstract
 
 
The role of pharmacological enhancement in protease inhibitor-based highly active
antiretroviral therapy.
 Becker SL
 Expert Opin Investig Drugs 2003 Mar;12(3):401-12
 Abstract
 
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a
randomized trial.
 Hammer SM, Vaida F, Bennett KK , et al.
JAMA 2002 Jul 10;288(2):169-80
 Abstract
 
 

 

 

 

     Conference Reports, Abstracts, and Posters

 
Pharmacokinetic of protease inhibitors based regimens in 6 liver transplantation
HIV-infected patients
Tavio M., Baccarani U., Londero A., Pea F., et al
(XVI International AIDS Conference)
 Abstract
 
A Randomized Trial of 1 or 2 Protease Inhibitors in Combination with a Non-nucleoside
Reverse Transcriptase Inhibitor and Background Therapy in Patients with Virologic Failure
on an Initial Protease-inhibitor Containing Regimen
 J Kostman, B Grund, R Leduc, et al
(11 CROI)
 Abstract
Diagnostics/Monitoring
 
     Journal Papers, Abstracts, and Commentaries
 
 
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.
Soliman EZ, Lundgren JD, Roediger MP,  et al
AIDS. 2010 Dec 9
 Abstract

Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients
depends on PI used in HAART regimen--ANRS 111 trial.
Duval X, Mentré F, Rey E, et al
 Fundam Clin Pharmacol. 2009 Aug;23(4):491-500
 Abstract

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced,
HIV-1-infected patients.
Demeter LM, Jiang H, Mukherjee AL, et al
AIDS. 2008 Dec 24
 Abstract

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase
inhibitor and protease inhibitor concentrations in human plasma.
 Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Oct 31;
Abstract
Non-HIV Indications
 
     Journal Papers, Abstracts, and Commentaries
 
 
Repositioning HIV protease inhibitors as cancer therapeutics.
Bernstein WB, Dennis PA.
 Curr Opin HIV AIDS. 2008 Nov;3(6):666-75.
 Abstract

Antileishmanial activity of HIV protease inhibitors.
Savoia D, Allice T, Tovo PA.
Int J Antimicrob Agents. 2005 Jun 12;
Abstract

Drugs Main Page HIV Main Page Main New/Newsworthy Home    

Protease Inhibitors Main Page


 

.